Entities / Company
Brainstorm.
company in Madrid, Spain
- Reports this week
- 0
- Active events
- 0
- Connections
- 15
What's happening
Gone quiet
No new reports in 90+ days-
Brainstorm and Loulou Foundation provided funding for rare genetic epilepsy initiatives and adopted FDA-encouraged methodologies.Some support1 report1 development inside
-
Case spoke at the Brainstorm Tech conference on June 12, 2026.Some support1 report
-
Brainstorm seeks accelerated approval for NurOwn treatment from the FDA.Speculative1 report
-
Brainstorm (Q30255242) faced non-compliance with minimum shareholder equity requirements on July 18, 2025, and secured approval for a continuous trading platform.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Brainstorm this week
News at the entities that move Brainstorm most-
MSC OperationalMSC launched direct and feeder services linking Karachi with Europe, capitalizing on shifting trade routes amid Middle East turmoil.Moves Brainstorm
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Brainstorm
Connections
The 5 strongest of 15, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Brainstorm's drug development is structurally dependent on FDA regulatory clearance and designation.
-
MSC Operational
MSC and Brainstorm are engaged in a partnership for the manufacturing and trial preparation of NurOwn therapy.
-
Loulou Foundation Transactional
Loulou Foundation provides funding for initiatives focused on rare genetic epilepsy at Brainstorm.
-
Als Mentioned together
Brainstorm is developing therapeutics targeting neurodegenerative diseases like ALS.
-
Case Mentioned together
Case participated as a speaker at a Brainstorm Tech conference.
History
Events by the month they beganJune 2026
4 events- Brainstorm and Loulou Foundation provided funding for rare genetic epilepsy initiatives and adopted FDA-encouraged methodologies.
- Case spoke at the Brainstorm Tech conference on June 12, 2026.
- Brainstorm seeks accelerated approval for NurOwn treatment from the FDA.
- Brainstorm (Q30255242) faced non-compliance with minimum shareholder equity requirements on July 18, 2025, and secured approval for a continuous trading platform.